Copyright
©The Author(s) 2021.
World J Hepatol. May 27, 2021; 13(5): 543-556
Published online May 27, 2021. doi: 10.4254/wjh.v13.i5.543
Published online May 27, 2021. doi: 10.4254/wjh.v13.i5.543
Cutoff | Total n | n of events | Estimated mean (mo) | Standard error | 95%CI |
BAS | |||||
Median cutoff of 2.19 | |||||
Low risk < 2.19 | 128 | 4 | 81.68 | 1.14 | 79.44-83.93 |
High risk > 2.19 | 129 | 23 | 70.72 | 2.5 | 65.81-75.62 |
Non-BAS | |||||
Median cutoff of 1.44 | |||||
Low risk < 1.44 | 118 | 9 | 78.68 | 1.70 | 75.34-82.02 |
High risk > 1.44 | 139 | 18 | 73.97 | 2.21 | 69.64-78.29 |
MELD | |||||
Median cutoff of 11 | |||||
Low risk < 11 | 133 | 11 | 78.06 | 1.71 | 74.71-81.42 |
High risk > 11 | 124 | 16 | 73.91 | 2.35 | 69.29-78.52 |
- Citation: Alamoudi JA, Li W, Gautam N, Olivera M, Meza J, Mukherjee S, Alnouti Y. Bile acid indices as biomarkers for liver diseases II: The bile acid score survival prognostic model. World J Hepatol 2021; 13(5): 543-556
- URL: https://www.wjgnet.com/1948-5182/full/v13/i5/543.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i5.543